Deborah Kaster Joins Adagio Medical as Chief Business Officer

Catheter ablation tech provider Adagio Medical has appointed Deborah Kaster as chief business officer (CBO). Kaster will oversee business development, strategic partnerships, investor relations and corporate communications, working as part of the senior leadership team to advance the company’s objectives and vision.

Kaster has more than 25 years of leadership experience in medtech strategy, mergers and acquisitions, corporate finance, investor relations, and strategic communications. She most recently served as vice president of Investor Relations at Shockwave Medical, where she played a pivotal role in the company’s growth from initial public offering to its acquisition by Johnson & Johnson. During her Shockwave tenure, the company’s stock price appreciated nearly 2,000%, a testament to her strategic vision and communications expertise.

“Debbie’s deep expertise in corporate strategy, business development and communications, combined with her relationships and experience on Wall Street, will be instrumental as Adagio Medical enters its next phase of growth,” Adagio Medical CEO Todd Usen said. “We are thrilled to welcome Debbie to the team and are confident that her leadership will drive value for our stakeholders and accelerate our mission to revolutionize treatment for patients with ventricular tachycardia.”

Kaster’s career spans a wide range of roles where she has demonstrated her ability to drive corporate strategy and business development. As director of Business Development at Kyphon, she led the company in a competitive bidding process for St. Francis Medical Technologies, which resulted in Kyphon’s $725 million acquisition of St. Francis Medical and, almost immediately subsequent, the ultimate $4 billion acquisition of Kyphon by Medtronic.

Kaster’s career includes senior roles at Gilmartin Group and in the medical technology investment banking group at Piper Jaffray. She has advised and led strategic initiatives for numerous public and private companies in the medical technology sector.

Kaster earned an MBA in finance and strategic management from The Wharton School at the University of Pennsylvania and a bachelor of arts degree in economics from Cornell University.

“I am excited to join Adagio Medical at such a transformative time for the company,” Kaster stated. “The potential to make a meaningful impact in the EP space is immense, and I look forward to contributing to Adagio’s success and helping drive the company’s growth strategy.”

Adagio Medical is developing and commercializing products for treating cardiac arrhythmias using its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on treating ventricular tachycardia (VT) with its purpose-built vCLAS catheter, which is CE Marked and is currently under evaluation in the FULCRUM-VT U.S. IDE Pivotal Study.